Basilea Pharmaceutica AG Stock
Stocks
BSLN
CH0011432447
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Swiss Exchange
01:30:36 03/10/26 am AEST
|
5-day change | 1st Jan Change | ||
| 66.80 CHF | -1.47% |
|
-2.77% | +22.12% |
| 14/09 | Japanese Stocks Fall on AI Development Slowdown Calls; Oil Gains | MT |
| 14/09 | Asahi Kasei Unit Starts Phase Two Study of Antifungal Cresemba for Pediatric Patients in Japan | MT |
| Market Cap | 830M 1B 889M 756M 1.43B 96.16B 1.44B 10.04B 3.89B 49.16B 3.76B 3.67B 158B | P/E 2026 * |
15.5x | P/E 2027 * | 17.3x |
|---|---|---|---|---|---|
| Enterprise Value | 677M 816M 725M 617M 1.16B 78.46B 1.17B 8.19B 3.17B 40.11B 3.06B 3B 129B | EV / Sales 2026 * |
2.53x | EV / Sales 2027 * | 2.22x |
| Free-Float |
91.74% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Swiss Exchange
| BSLN | Delayed | |
London S.E.
| 0QNA | Delayed | |
|
CBOE
| 0QNA | Real-time | |
|
Tradegate
| PK5 | Real-time | |
|
OTC Markets
| BPMUF | Delayed | |
|
Börse Stuttgart
| PK5 | Delayed | |
|
Boerse Muenchen
| PK5 | Real-time | |
|
Deutsche Boerse AG
| PK5 | Delayed |
Last Transcript: Basilea Pharmaceutica AG
| 1 day | -1.47% | ||
| 1 week | -2.77% | ||
| Current month | -4.43% | ||
| 1 month | +1.67% | ||
| 3 months | +25.80% | ||
| 6 months | +21.23% | ||
| Current year | +22.12% |
| 1 week | 66.3 |  | 70.1 |
| 1 month | 62.2 | | 70.5 |
| Current year | 47.8 | | 70.5 |
| 1 year | 44.7 | | 70.5 |
| 3 years | 32 | | 70.5 |
| 5 years | 29.55 | | 70.5 |
| 10 years | 29.28 | | 95.35 |
| Manager | Title | Age | Since |
|---|---|---|---|
David Veitch
CEO | Chief Executive Officer | 61 | 19/04/2018 |
Adesh Kaul
DFI | Director of Finance/CFO | 52 | 10/04/2019 |
Gerrit Hauck
CTO | Chief Tech/Sci/R&D Officer | 62 | 01/05/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Thomas Werner
BRD | Director/Board Member | 70 | 29/11/2011 |
| Chairman | 71 | 09/04/2013 | |
Nicole Onetto
BRD | Director/Board Member | 73 | 27/04/2017 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 29/5/26 | Sell | -400 | 0.0030% | |||
| 13/5/26 | Sell | -1,043 | 0.0078% | |||
| 4/5/26 | Sell | 400 | 0.0030% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.47% | -2.77% | +38.59% | +58.67% | 1B | |
| +4.16% | +3.04% | +49.37% | +94.17% | 74.16B | |
| -3.11% | -3.53% | +21.92% | +74.60% | 57.39B | |
| +0.89% | -0.63% | +4.28% | +34.51% | 47.64B | |
| +0.36% | +0.81% | +352.17% | +689.61% | 44.29B | |
| -0.96% | -4.50% | +26.36% | +33.18% | 42.5B | |
| -0.20% | -0.77% | +3.74% | +100.60% | 40.71B | |
| -0.54% | +2.93% | +9.31% | +50.41% | 30.97B | |
| -2.68% | +2.92% | +29.63% | +19.50% | 28.53B | |
| +0.05% | -1.64% | -7.28% | -14.06% | 24.34B | |
| Average | -0.35% | -0.81% | +52.81% | +114.12% | 39.15B | |
| Weighted average by Cap. | +0.12% | -0.84% | +58.71% | +129.73% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 268M 323M 287M 244M 461M 31.06B 465M 3.24B 1.26B 15.88B 1.21B 1.19B 50.96B | 275M 332M 295M 251M 473M 31.9B 477M 3.33B 1.29B 16.31B 1.25B 1.22B 52.34B |
| Net income | 68.7M 82.84M 73.6M 62.61M 118M 7.96B 119M 831M 322M 4.07B 311M 304M 13.07B | 58.3M 70.3M 62.47M 53.14M 100M 6.76B 101M 706M 273M 3.46B 264M 258M 11.09B |
| Net Debt | -153M -184M -164M -139M -262M -17.7B -265M -1.85B -716M -9.05B -691M -676M -29.04B | -218M -263M -233M -199M -375M -25.26B -378M -2.64B -1.02B -12.91B -986M -965M -41.44B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/10/26 | CHF 66.80 | -1.47% | 17,311 |
| 01/10/26 | CHF 67.80 | -3.00% | 24,214 |
| 30/09/26 | CHF 69.90 | +4.33% | 45,860 |
| 29/09/26 | CHF 67.00 | -1.90% | 20,986 |
| 28/09/26 | CHF 68.30 | -0.58% | 15,529 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- BSLN Stock
Select your edition
All financial news and data tailored to specific country editions
